NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Management of Renal Masses and Localized Renal Cancer
Comparative Effectiveness Reviews, No. 167
Investigators: Phillip M Pierorazio, MD, Michael H Johnson, MD, Hiten D Patel, MD, MPH, Stephen M Sozio, MD, MHS, Ritu Sharma, BSc, Emmanuel Iyoha, MBChB, MPH, Eric B Bass, MD, MPH, and Mohamad E Allaf, MD.
Author Information and AffiliationsStructured Abstract
Objectives:
To summarize the evidence on the effectiveness and comparative effectiveness of strategies for evaluating and treating patients with a renal mass suspicious for renal cell carcinoma, including use of composite models for predicting malignancy at initial diagnosis, use of percutaneous renal sampling (by fine needle aspiration or core biopsy) to establish a diagnosis, and comparative efficacy of radical nephrectomy, partial nephrectomy, thermal ablation, and active surveillance.
Data sources:
We searched MEDLINE®, Embase®, and the Cochrane Central Register of Controlled Trials (CENTRAL) from January 1, 1997, through May 1, 2015, and we looked for studies on Clinicaltrials.gov.
Review methods:
Paired investigators independently screened search results to assess eligibility. Investigators abstracted data sequentially and assessed risk of bias independently. Investigators graded the strength of evidence as a group.
Results:
The search identified 147 studies, published in 150 articles. In preoperative composite models of patient and tumor characteristics, male sex and increased tumor size were consistently predictive of malignant pathology. The diagnostic accuracy of core biopsy was evaluated in 18 studies, and had a sensitivity of 97.5 percent, specificity of 96.2 percent, positive predictive value of 99.8 percent, negative predictive value of 68.5 percent, non-diagnostic rate of 14 percent, and complication rate of 5 percent or less. Only one study examined the diagnostic accuracy of fine needle aspiration (sensitivity 63 percent). Cancer-specific survival was excellent among all management strategies with a median 5-year cancer-specific survival of 95 percent. Overall survival rates were 75-99 percent for partial nephrectomy, 71-81 percent for radical nephrectomy, and 83-95 percent for thermal ablation (at 5 years), and 69-94 percent for active surveillance (at 12-35 months). The strength of evidence was low to moderate that local recurrence-free survival was worse for thermal ablation than for radical or partial nephrectomy, but equivalent with partial nephrectomy when multiple ablative treatments were considered. The strength of evidence was moderate that radical nephrectomy had the largest decline in estimated glomerular filtration rate and highest incidence of chronic kidney disease, but the rate of end-stage renal disease was low among all management strategies (0.4-2.8 percent). The strength of evidence was moderate that thermal ablation offered more favorable perioperative outcomes (estimated blood loss, length of hospital stay, and conversion to open surgery), but all interventional strategies were approximately equivalent when evaluating postoperative harms. However, the strength of evidence was low that partial nephrectomy was associated with greater urologic complications, bleeding, and blood transfusion rate, and radical nephrectomy had more respiratory harms and acute kidney injury when compared to partial nephrectomy and thermal ablation.
Conclusions:
No composite model reliably predicts malignancy, although tumor size and male sex are highly associated with malignancy. Percutaneous renal mass sampling with core biopsy is a low risk and sensitive procedure, but is associated with a notable non-diagnostic rate (14 percent). Most patients with non-diagnostic biopsies who proceed to surgery are found to have malignancy. Cancer-specific survival was comparable across all management strategies, with differences in overall survival that are explained by competing risks of death. Thermal ablation has the highest local recurrence rate and may require multiple treatments to achieve similar oncologic efficacy as radical or partial nephrectomy. However, thermal ablation has the most favorable perioperative outcomes and harms. Thermal ablation and partial nephrectomy offer improved renal functional outcomes over radical nephrectomy in the long run. Comparative data are lacking on active surveillance. Therefore, selection of a management strategy warrants a conversation between patient and physician to discuss the outcome profile for each strategy based on similar cancer-specific survival but different overall survival (competing health risks), renal functional outcomes, perioperative outcomes, and postoperative harms.
Contents
- Preface
- Acknowledgments
- Key Informants
- Technical Expert Panel
- Peer Reviewers
- Executive Summary
- Introduction
- Methods
- Results
- Results of the Search
- Overview of Included Studies by KQs
- Organization of Results Chapter
- KQ 1 Efficacy of Composite Models in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma
- KQs 2a and 2b Accuracy and Efficacy of Renal Mass Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma
- KQ 3a Efficacy and Comparative Efficacy of Different Interventions for the Management of a Renal Mass Suspicious for Localized Renal Cell Carcinoma
- KQ 3b Comparative Benefits and Harms of Management Strategies Based on Patient Demographics, Clinical Characteristics, or Disease Severity
- Discussion
- Conclusions
- References
- Appendix A Detailed Electronic Database Search Strategies
- Appendix B Screening and Data Abstraction Forms
- Appendix C List of Excluded Studies
- Appendix D Evidence Tables
- Appendix E Uncontrolled Studies
- Appendix F Meta-Analysis Figures
- Appendix G Clinical Trials Report
Prepared for: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services1. Contract No. 290-2012-00007-I. Prepared by: Johns Hopkins University Evidence-based Practice Center, Baltimore, MD
Suggested citation:
Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME. Management of Renal Masses and Localized Renal Cancer. Comparative Effectiveness Review No. 167. (Prepared by the JHU Evidence-based Practice Center under Contract No. 290-2012-00007-I.) AHRQ Publication No. 16-EHC001-EF. Rockville, MD: Agency for Healthcare Research and Quality. February 2016. www.effectivehealthcare.ahrq.gov/reports/final.cfm.
This report is based on research conducted by the Johns Hopkins University Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2012-00007-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.
None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.
The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.
AHRQ or U.S. Department of Health and Human Services endorsement of any derivative products that may be developed from this report, such as clinical practice guidelines, other quality enhancement tools, or reimbursement or coverage policies may not be stated or implied.
This report may periodically be assessed for the currency of conclusions. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at www.effectivehealthcare.ahrq.gov. Search on the title of the report.
- 1
5600 Fishers Lane, Rockville, MD 20857; www
.ahrq.gov
- NLM CatalogRelated NLM Catalog Entries
- Review Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis.[J Urol. 2016]Review Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis.Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME. J Urol. 2016 Oct; 196(4):989-99. Epub 2016 May 6.
- Review Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis.[Clin J Am Soc Nephrol. 2017]Review Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis.Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Allaf ME, Bass EB, Sozio SM. Clin J Am Soc Nephrol. 2017 Jul 7; 12(7):1057-1069. Epub 2017 May 8.
- Review Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the U.S. Preventive Services Task ForceWernli KJ, Henrikson NB, Morrison CC, Nguyen M, Pocobelli G, Whitlock EP. 2016 Jul
- Review Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2016]Review Lipid Screening in Childhood for Detection of Multifactorial Dyslipidemia: A Systematic Evidence Review for the U.S. Preventive Services Task ForceLozano P, Henrikson NB, Morrison CC, Dunn J, Nguyen M, Blasi P, Whitlock EP. 2016 Aug
- Review A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer.[Eur Urol. 2010]Review A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer.Heuer R, Gill IS, Guazzoni G, Kirkali Z, Marberger M, Richie JP, de la Rosette JJ. Eur Urol. 2010 Feb; 57(2):223-32. Epub 2009 Oct 20.
- Management of Renal Masses and Localized Renal CancerManagement of Renal Masses and Localized Renal Cancer
Your browsing activity is empty.
Activity recording is turned off.
See more...